Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Treatment and Management of Schizophrenia in Europe
NL-OMON41244Phase 3Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amisulpride, olanzapine and clozapine in schizophrenia, schizophreniform disorder, schizoaffective disorder and 1 more (6 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Medication component remission, Psychosocial intervention adherence and functioning and 3 more. Started Oct 2011; status: active, not recruiting.
02
Drugs
amisulprideolanzapineclozapine
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on NL-OMON41244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41244.